Home > Papers

 
 
LAPTM4B Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Local Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy
Fanling Meng 1 #,Pan shang 2,Hongtao Song 3,Ge Lou 1 *
1.Department of Gynecology, the Affliated Tumor Hospital of Harbin University, Harbin, Chian.
2.Department of Gynecology, Taizhou people hospitle, Taizhou, Chian.
3.Department of Pathology, the Affliated Tumor Hospital of Harbin University, Harbin, Chian.
*Correspondence author
#Submitted by
Subject:
Funding: Grant support: This work was supported by grants of the Specialized Research Fund for the Doctoral Program of Higher Education （No.20122307120027), the Postdoctoral Foundation of Heilongjiang Province of China）
Opened online:14 June 2016
Accepted by: none
Citation: Fanling Meng,Pan shang,Hongtao Song.LAPTM4B Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Local Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy[OL]. [14 June 2016] http://en.paper.edu.cn/en_releasepaper/content/4693514
 
 
Objectives: LAPTM4B (lysosomal protein transmembrane-4 beta) plays a critical role in tumor progression and chemoresistance. The aim of this study was to evaluate the significance of LAPTM4B expression to predict response to platinum-based neoadjuvant chemotherapy and survival of patients with locally advanced cervical cancer (LACC) who subsequently underwent radical hysterectomy. Materials and methods: Biopsy specimens of cervical cancer before neoadjuvant chemotherapy were obtained from 116 patients who subsequently underwent radical hysterectomy. The expression of LAPTM4B protein was analyzed by immunohistochemistry. Findings were evaluated in relation to LAPTM4B expression and chemotherapy resistance. Survival analyses were performed by the Kaplan-Meier curves and a Cox regression model to determine overall survival (OS) and disease-free survival (DFS). Results: Our result showed that LAPTM4B was highly expressed in 73.3% of LACC sections. Expression of LAPTM4B was significantly associated with poor clinical response (P=0.012). Moreover, high expression of LAPTM4B was significantly associated with poor OS and DFS compared with the low expression group (both P<0.05). Multivariate analysis revealed that LAPTM4B expression was an independent prognostic factor for OS (P<0.05). Conclusions: In conclusion, elevated LAPTM4B expression in patients with locally advanced cervical cancer contributes to chemoresistance and predicts poor prognosis.
Keywords:LAPTM4B; Neoadjuvant chemotherapy; Locally advanced cervical cancer; Immunohistochemistry
 
 
 

For this paper
  • ● PDF (0B)
  • ● Revision 0 　　
  • ● Print this paper
  • ● Recommend this paper to a friend
  • ● Add to my favorite list

    Saved Papers

    Please enter a name for this paper to be shown in your personalized Saved Papers list

Tags
Add yours

Related Papers

Statistics
PDF Downloaded 32
Bookmarked 0
Recommend 0
Comments Array
Submit your papers